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Abstract
Rationale Numerous studies suggest agents that act on gluta-
matergic transmission as potential antidepressants. Preclinical
and clinical evidence suggests that magnesium, an N-methyl-
D-aspartate receptor blocker, may be useful in the treatment of
depression.
Objective The aim of this study was to investigate the effects
of magnesium on behavior; protein levels of GluN2A,
GluN2B [N-methyl-D-aspartate receptor (NMDAR) subunits],
GluA1 [α-amino-3-hydroxy-5 methyl-4-isoxazolepropionic
acid (AMPA) subunit], phospho-Ser-831-GluA1 (P-S831),
phospho-Ser-845-GluA1 (P-S845), and brain-derived neuro-
trophic factor (BDNF); and messenger RNA (mRNA) levels
of GluN2A and GluN2B in different brain areas in the olfac-
tory bulbectomy (OB) model of depression in rats.
Methods Magnesiumwas administered once daily for 14 days
at three doses (10, 15, and 20 mg/kg, intraperitoneal) to sham
and OB rats. Following treatment, open field and passive
avoidance tests were performed in the sham and OB rats.
After 24 h, the hippocampus, the prefrontal cortex (PFC),
and the amygdala of rats treated with the most active dose
(15 mg/kg) were harvested, and the protein and mRNA levels
were determined.
Results Chronic administration of magnesium (15 and
20 mg/kg) reduced the number of trials required to learn
passive avoidance and reduced the OB-induced hyperactivity.
OB increased the P-S845 level in the hippocampus, which
was reduced by magnesium treatment. Magnesium signifi-
cantly increased the levels of BDNF, GluN2B, P-S831, and
P-S845 protein (and mRNA) primarily in the PFC and the
hippocampus in OB rats.
Conclusion For the first time, the present results demonstrate
the antidepressant-like activity of magnesium in the OB ani-
mal model of depression and indicate the potential involve-
ment of the AMPA/BDNF pathway in this activity.
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Introduction
Numerous recent studies have indicated agents that act on
glutamatergic transmission function as potential alternative
approaches in the pharmacological treatment of depression
(Li et al. 2010; Autry et al. 2011; Lima-Ojeda et al. 2013).
The most promising results have arisen from trials with N-
methyl-D-aspartate receptor (NMDAR) antagonists. The anti-
depressant activity of ketamine, a nonselective antagonist of
NMDARs, has been known for many years (Berman et al.
2000). The clinical effects of ketamine have been observed
within hours and occur in patients resistant to typical antide-
pressant drugs and in patients with resistance in bipolar dis-
order (Zarate et al. 2006, 2012). The activation of glutamater-
gic transmission achieved by ketamine leads to several chang-
es, such as the potentiation of α-amino-3-hydroxy-5 methyl-
4-isoxazolepropionic acid receptor (AMPARs), the activation
of the mammalian target of rapamycin (mTOR), and an inten-
sified release of brain-derived neurotrophic factor (BDNF) (Li
et al. 2010). The potentiation of AMPARs depends on numer-
ous modifications that change the receptor’s functional state;
the most well-known modifications include the phosphoryla-
tion of S-831of Ca2+/calmodulin (CaMKII), protein kinase C
(PKC), and S-845 protein kinase A (PKA) (Lee et al. 2010;
Lee and Kirkwood. 2011).
The functional state of NMDARs is also regulated by
natural factors, such as magnesium and zinc (Szewczyk
et al. 2012). Blockade of the NMDAR’s ion channel is the
most established mechanism involved in magnesium’s action
in the central nervous system (CNS) (Paoletti et al. 1995). In
clinical studies, many patients with mood disorders have
altered plasma/serum magnesium concentrations (Serefko
et al. 2013). A lower level of magnesium has been identified
in patients with long-lasting and unipolar depression (Kirov
et al. 1994). In cases of acute depression, such effects have not
been observed (Linder et al. 1989; Hashizume and Mori
1990).
The importance of magnesium for the normal function-
ing of the CNS has also been corroborated in preclinical
studies that have revealed a deficiency of magnesium
induces depressive-like behavior and anxiety that are re-
versed by antidepressant treatment (Singewald et al.
2004). Preclinical studies have also indicated that magne-
sium is an antidepressant agent that acts through the
NMDA pathway. It has been demonstrated that the
antidepressant-like activity of magnesium in the forced
swim test (FST) was antagonized by agonists of
NMDARs, such as D-serine and NMDA. Furthermore,
the administration of ineffective doses of magnesium in
combination with ineffective doses of NMDAR antago-
nists (e.g., CGP 37849, D-cycloserine, L-701,324, or MK-
801) has been shown to cause a significant reduction in
the immobility time in the FST (Decollogne et al. 1997;
Poleszak et al. 2007, 2008). The hypothesis that magne-
sium is a potential agent in the treatment of depression is
also enhanced by our previous studies that evaluated
magnesium efficacy in the chronic mild stress (CMS)
model of depression. This study examined the activity of
magnesium in the sucrose intake test, which measures
anhedonia as the core symptom of depression (Pochwat
et al. 2014).
Our present study examined the antidepressant poten-
tial of magnesium (10, 15, and 20 mg/kg) in the bilateral
olfactory bulbectomy model (OB), which is a widely
accepted animal model of agitated depression (Kelly
et al. 1997); importantly, agitated depression is a major
risk factor for suicide (Rihmer 2007). Behavioral changes
and the affinity of magnesium to reverse abnormalities
caused by the removal of the olfactory bulbs were deter-
mined in the open field and passive avoidance tests. For
the biochemical assays, we selected the dose of 15 mg/
kg, which is the dose active in both tests as well as in
the CMS paradigm (Pochwat et al. 2014). Autoradiogra-
phy data from animal studies show a reduced level of
NMDARs in OB rats (Robichaud et al. 2001), and the
other study suggested that OB reduced the potency of
glycine to inhibit [3H] 5,7-DCKA binding (Nowak
1996). As a result of this and other studies that indicated
OB influence on ionotropic glutamate receptors (Song
and Leonard 2005), we directed our efforts to study the
changes in the protein levels of GluN2A, GluN2B sub-
units of NMDARs, and GluA1 subunit of AMPARs.
Additional evidence to support this approach was obtain-
ed from human postmortem data that demonstrated de-
creased hippocampal and cortical levels of the GluN2B
subunit of NMDARs in patients with MDD (Feyissa
et al. 2009; Sowa-Kucma et al. 2013). In view of the
crucial role of the GluA1 subunit in the control level of
BDNF (Li et al. 2010) and the antidepressant-like activ-
ity of NMDAR antagonists, the levels of phospho-Ser-
831-GluA1 (P-S831) and phospho-Ser-845-GluA1 (P-
S845) of the GluA1 subunit and BDNF were also deter-
mined. We performed all assays in the PFC, the hippo-
campus, and the amygdala, which are critical structures
for the development of human depression (Nestler et al.
2002) and depressive-like symptoms in OB rats (Song
and Leonard 2005). For comparison with protein expres-
sion, we evaluated the expression levels of the GluN2A
and GluN2B mRNA subunits in the PFC and the
hippocampus.
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Material and methods
Animals and housing
All procedures were conducted according to the National
Institute of Health Animal Care and Use Committee guide-
lines and were approved by the Ethical Committee of the
Institute of Pharmacology, Krakow. The experiments were
performed on male Sprague-Dawley rats (220–250 g). The
animals were maintained on a normal day-night cycle (light
phase 7:00–19:00) and temperature (19–21 °C) with free
access to food and water. Each experimental group consisted
of six to eight animals. All animals were first subjected to the
open field test and to the passive avoidance test 2 days later.
The experiments were performed during the light period
(9:00–14:00 h).
Olfactory bulbectomy—surgical procedure
One week after their arrival to the laboratory, a bilateral
olfactory bulbectomy was performed on the rats under keta-
mine (100 mg/kg)/xylazine (10 mg/kg) anesthesia.
Metoxicam (0.05 mg/kg, subcutaneous) was administered as
an analgesic and anti-inflammatory drug prior to the operation
and 2 days after the surgery. Following the exposure of the
skull, burr holes were drilled (7 mm anterior to the bregma).
The olfactory bulbs were removed by suction, and the burr
holes were filled with a hemostatic sponge (Ferrosan, Poland).
The skin was then closed. The sham-operated animals were
treated similarly, but the bulbs were left intact. The animals
were allowed to recover for 14 days following surgery. During
this time, they were handled daily by the experimenter to
prevent the development of aggressive behavior.
Amitriptyline (10 mg/kg) and magnesium hydroaspartate
(10, 15, and 20 mg/kg, calculated as magnesium ions) were
chronically administered once daily for 14 days between 8:00
and 10:00 a.m. via an intraperitoneal (i.p.) injection. Twenty-
four hours after the last dose, the open field test was per-
formed. Drug treatment was continued to the next day. The
passive avoidance test was conducted 2 days after the open
field test and 24 h after drug administration (Fig. 1). The
control animals received a vehicle solution (0.9 % sodium
chloride). The drugs were injected at a constant volume of
2 ml/kg.
Open field test
The open field test was performed using an “open field”
apparatus (an arena 90 cm in diameter, divided into 10 cm
squares by faint yellow lines). The arena was surrounded by a
75-cm high aluminum sheet. All measurements were per-
formed in a darkened room. Illumination was provided by a
60-W bulb which was positioned 90 cm above the floor. Each
rat was placed individually in the center of the open field and
allowed to freely explore it for 3 min. The behaviors of interest
included episodes of rearing, defined as raising the forepaws
from the floor, and ambulation, defined as the number of
sector lines crossed (once a line had been crossed with all four
paws).
Passive avoidance test
The passive avoidance test was performed using a Plexiglas
box (50 cm×50 cm×50 cm) with a grid floor. The grid floor
consisted of parallel steel rods set 1.2 cm apart. A wooden
platform (12 cm×12 cm×4 cm) was placed in the center of the
grid floor where the rats were placed individually. Once the rat
left the platform with all four paws, it received an electric
shock 0.75 mA/1 s). The animals were then immediately
removed from the experimental cage and transferred to the
home cage. After 30 s, the next trial on the same rats was
initiated. The training was stopped if the rats learned to not
leave the platform before the passage of 1 min or if 15 trials
occurred.
Western blot analysis
Twenty-four hours after the last dose of magnesium, the
animals were killed and their brains were collected. The
hippocampus, the amygdala, and the prefrontal cortex were
rapidly dissected. The tissues were frozen on dry ice and
stored at −80 °C. In the next step, they were homogenized in
ice in a 2 % solution of sodium dodecyl sulfate (SDS). The
homogenates were subsequently denatured at 95 °C for
10 min and centrifuged for 5 min at 10,000 rpm at 4 °C. After
centrifugation, the supernatant was collected and the protein
content was determined. For this assay, bicinchonic acid was
used (Pierce). Next, the samples were fractionated by 10 %
SDS-polyacrylamide gel electrophoresis. In a further step, the
Fig. 1 Schedule of the
experimental procedure
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proteins were transferred to a nitrocellulose membrane
(Invitrogen, Paisley, UK). To block nonspecific binding, a
1 % blocking solution was used (BM Chemiluminescence
Western Blotting Kit (Mouse/Rabbit), Roche). After blocking,
the membranes were incubated overnight at 4 °C with the
respective antibodies. The following antibodies were used:
polyclonal anti-NMDAR2A antibody (Abcam), diluted
1:1,000; polyclonal anti-NMDAR2B antibody (Abcam), di-
luted 1:1,000; polyclonal AMPAR GluA1 antibody (Abcam),
monoclonal anti-P-S831, and monoclonal anti-P-S845
(Abcam), all diluted 1:1,000; and polyclonal BDNF (Santa
Cruz Biotechnology), 1:500 diluted. All antibodies were dis-
solved in 0.5 % blocking reagent (Roche). The next day, the
membranes were washed three times for 10 min in Tris-
buffered saline with Tween (TBS-T) and incubated for
30 min with anti-mouse IgG-peroxidase-conjugated anti-
rabbit-IgG-peroxidase-conjugated antibodies (diluted
1:7,000). This set of secondary antibodies was also a compo-
nent of the BM Chemiluminescence Western Blotting Kit
(Mouse/Rabbit) (Roche). After incubation, the membranes
were washed three times for 10 min with TBS-T. In the last
step, the blots were incubated with a detection reagent
(Roche). The signal from the tested proteins was visualized
and measured using the Fuji-Las 1000 system and Fuji Image
Gauge v.4.0 software (Fig. 10). To confirm the transfer and
loading, β-actin was indicated on each blot using a primary
monoclonal antibody (Millipore; 1:8,000; Fig. 10). The pro-
cedures were the same for the other proteins. The final results
are provided as the ratio of the optical density of specific
proteins to the optical density of β-actin.
RNA isolation and real-time RT-PCR
The tissue samples were homogenized in TissueLyser
(Qiagen, Germany) and immediately subjected to RNA isola-
tion with TRIzol reagent (Invitrogen). The integrity of the
obtained RNA was confirmed by gel electrophoresis. The
RNA purity and concentration were assessed with a Nanodrop
spectrophotometer (Thermo Scientific, USA). Onemicrogram
of total RNA from each sample was digested with DNase I
(Sigma-Aldrich, Germany) and reverse-transcribed into com-
plementary DNA (cDNA) using the High Capacity cDNA
Reverse Transcription Kit with random hexamers (Applied
Biosystems, USA). Real-time polymerase chain reactions
(PCRs) were conducted on a CFX96 Real-Time System
(Bio-Rad, USA) and C1000 Touch Thermal Cycler (Bio-
Rad) using 96-well optical plates (Bio-Rad). The 18-μl PCR
reaction mixtures included the following: 1.8 μl of cDNA
sample (diluted 1:10 in RNase-free water), Power SYBR
Green Master Mix (Applied Biosystems), and primers in
concentrations of 200 nM each. The primer sequences are
shown in Table 1. The Basic Local Alignment Search Tool
(BLAST) from the National Center for Biotechnology
Information (NCBI) was used to preclude the homology of
the primers used for any other sequences in the database. The
PCR reactions were incubated at 95 °C for 10min followed by
40 cycles at 95 °C for 15 s and 60 °C for 1 min. Then, a melt
curve was drawn for each primer pair to ensure that there was
no primer–dimer formation. Glyceraldehyde-3-phosphate de-
hydrogenase (Gapdh) was used as the endogenous reference
gene. All reactions were performed in triplicate, and the
average threshold cycle (CT) values were calculated. For each
sample, the CT value of the endogenous reference gene was
subtracted from the CT values of the target genes to obtain the
ΔCT values and to normalize the PCRs for the amount of
cDNA added to the subsequent reactions. For graphical pre-
sentation and statistical analysis, relative mRNA level indexes
of GluN2A and GluN2B genes were generated with the 2−ΔCT
formula (Livak and Schmittgen 2001).
Statistical analysis
All of the results are shown as the means ± SEM; the data were
analyzed by two-way ANOVA followed by the Newman–
Keuls test (behavioral studies) or the Bonferroni multiple
comparison test (biochemical studies). p<0.05 was consid-
ered statistically significant.
Results
Effects of OB and the administration ofmagnesium on passive
avoidance acquisition and number of ambulations in the open
field test
As shown in Fig. 2a, the OB procedure increased the activity
of the rats in the open field test, which was expressed as an
increase in the number of ambulations (###p=0.0002 NaCl
sham vs. NaCl OB). An amitriptyline dose of 10 mg/kg and
magnesium doses of 10, 15, and 20 mg/kg reversed this effect
in the OB animals (*p=0.03 AMI OB vs. NaCl OB; *p=
0.01 Mg10 OB vs. NaCl OB; *p=0.04 Mg15 OB vs. NaCl
OB; *p=0.01 Mg20 OB vs. NaCl OB). Chronic treatment
with amitriptyline or magnesium had no effect in the sham
Table 1 Real-time PCR primers used in this study (5' to 3')
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group. Two-way ANOVA demonstrated a significant effect of
OB [F(1, 64)=17.15, p=0.0001], no significant effect of
treatment [F(4, 64)=1.64, p=0.176], and a significant inter-
action [F(4, 64)=5.73, p=0.0005].
As shown in Fig. 2b, the removal of olfactory bulbs im-
paired passive avoidance acquisition (###p=0.0001 NaCl
sham vs. NaCl OB). Chronic treatment with an amitriptyline
dose of 10 mg/kg and magnesium doses of 15 and 20 mg/kg
significantly reduced the number of trials required to learn
passive avoidance in the OB animals (**p=0.002 AMI OB
vs. NaCl OB; *p=0.0.01 Mg15 OB vs. NaCl OB;
*p=0.01 Mg20 OB vs. NaCl OB). Two-way ANOVA dem-
onstrated significant effects of OB [F(1, 65)=85.32,
p=0.0001] and treatment [F(4, 65)=2.89, p=0.029], but no
significant interaction [F(4, 65)=1.91, p=0.119].
Effects of OB and administration of magnesium
on the GluN2A subunit level
As shown in Fig. 3, the OB procedure and magnesium treat-
ment did not induce significant effects in the GluN2A subunit
levels in the PFC (a), the hippocampus (b), or the amygdala (c).
In the prefrontal cortex, two-way ANOVA indicated that there
were no significant effect of OB [F(1, 18)=0.57, p=0.4590] or
magnesium [F(1, 18)=0.01, p=0.9302] and no significant in-
teraction [F(1, 18)=0.43, p=0.5220]. In the hippocampus, two-
way ANOVA indicated that there were no significant effect of
OB [F(1, 22)=0.79, p=0.3837] or magnesium [F(1, 22)=0.2,
p=0.6584] and no significant interaction [F(1, 22)=1.56, p=
0.2243]. In the amygdala, two-way ANOVA indicated that
there were no significant effect of OB [F(1, 20=0.0, p=
0.9868] or magnesium [F(1, 20)=0.58, p=0.4555] and no
significant interaction [F(1, 20)=0.38, p=0.5454].
Effects of OB and administration of magnesium
on the GluN2B subunit level
As shown in Fig. 4, the OB procedure and magnesium treat-
ment did not induce significant effects in the GluN2B subunit
levels in the PFC (a), the hippocampus (b), or the amygdala (c)
with one exception, that is, when magnesium treatment in the
OB animals induced an increased GluN2B subunit level in the
amygdala (215 % of NaCl sham, p<0.05 vs. NaCl OB,
Fig. 4c). In the PFC, two-way ANOVA indicated that there
Fig. 2 The effect of amitriptyline
(10 mg/kg) and magnesium (10,
15, and 20 mg/kg, i.p.) treatment
on the activity of rats in the open
field test (a) and the number of
trials in the passive avoidance test
(b). All compounds were
administered for 14 days. On the
15th day of chronic amitriptyline
and magnesium treatment, the
open field test followed by the
passive avoidance test (next day)
was performed. The values
represent the mean±SEM, n=7-8
and were analyzed by one-way
ANOVA followed by Newman–
Keuls test. ###p<0.001, relative
to NaCl sham; **p<0.01, *p<0.05
relative to NaCl OB. Seven to eight
animals per group were used
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were no significant effect of OB [F(1, 27=0.6, p=0.4443] or
magnesium [F(1, 27)=1.90, p=0.1791] and no significant
interaction [F(1, 27)=0.23, p=0.6382]. In the hippocampus,
two-way ANOVA indicated that there were no significant
effect of OB [F(1, 21)=0.08, p=0.779] or magnesium [F(1,
21)=3.44, p=0.0776] and no significant interaction [F(1,
21)=0.12, p=0.73]. In the amygdala, two-way ANOVA indi-
cated that there were no significant effect of OB [F(1, 21)=
0.39, p=0.5371], a very significant effect of magnesium [F(1,
21=10.21, p=0.0043], and no significant interaction [F(1,
21)=1.15, p=0.2962].
Effects of OB and administration of magnesium on the GluA1
subunit level
As shown in Fig. 5, the OB procedure and administration of
magnesium did not induce significant effects in the GluA1
subunit levels in the PFC (a), the hippocampus (b), or the
amygdala (c). In the PFC, two-way ANOVA indicated that there
were no significant effect of OB [F(1, 26)=0.05, p=0.8192] or
magnesium [F(1, 26)=1.81, p=0.1841] and no significant inter-
action [F(1, 26)=1.15, p=0.2929]. In the hippocampus, two-
way ANOVA indicated that there were no significant effect of
OB [F(1, 21=0.05, p=0.82] or magnesium [F(1, 21)=0.19, p=
0.6668] and no significant interaction [F(1, 21)=0.41, p=
0.5312]. In the amygdala, two-way ANOVA indicated that there
were no significant effect of OB [F(1, 27=0.45, p=0.5090] or
magnesium [F(1, 27)=0.99, p=0.3283] and no significant inter-
action [F(1, 27)=1.42, p=0.2432].
Effects of OB and administration of magnesium
on the P-S831 of the GluA1 subunit level
As shown in Fig. 6, the OB procedure and administra-
tion of magnesium did not induce significant effects in
Fig. 3 Changes in the protein levels of the GluN2A subunit of the
NMDA receptor induced by OB and magnesium treatment. The levels
of the GluN2A subunit were measured in the prefrontal cortex (a), the
hippocampus (b), and amygdala (c) of sham and OB rats, treated for
2 weeks with a vehicle or magnesium. The values represent the mean ±
SEM (n=7–8)
Fig. 4 Changes in the protein levels of the GluN2B subunit of the
NMDA receptor induced by OB and magnesium treatment. The levels
of the GluN2B subunit were measured in the prefrontal cortex (a), the
hippocampus (b), and amygdala (c) of sham and OB rats, treated for
2 weeks with a vehicle or magnesium. The values represent the mean ±
SEM (n=7–8). *p<0.05 vs. OB
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the P-S831 of GluA1 subunit levels in the PFC (a), the
hippocampus (b), or the amygdala (c) with one excep-
tion, that is, when magnesium treatment in the OB
animals induced an increase of P-S831 of the GluA1
subunit level in the PFC (177 % of NaCl sham,
p<0.05 vs. NaCl OB; Fig. 6a). In the PFC, two-way
ANOVA indicated significant effects of OB [F(1, 22)=
5.15, p=0.0335] and magnesium [F(1, 22)=6.94, p=
0.0151], but no significant interaction [F(1, 22)=1.43,
p=0.2446]. In the hippocampus, two-way ANOVA in-
dicated that there were no significant effect of OB
[F(1, 18=0.49, p=0.4950] or magnesium [F(1, 18)=
0.16, p=0.6934] and no significant interaction [F(1,
18) =0.80, p=0.3720]. In the amygdala, two-way
ANOVA indicated that there were no significant effect
of OB [F(1, 23=0.03, p=0.8739] or magnesium [F(1,
23)=1.83, p=0.1892] and no significant interaction
[F(1, 23)=0.78, p=0.3869].
Effects of OB and administration of magnesium
on the P-S845 of the GluA1 subunit level
As shown in Fig. 7, the OB procedure and administration of
magnesium did not induce significant effects in the P-S845 of
GluA1 subunit levels in the PFC (a), the hippocampus (b), or
the amygdala (c) with two exceptions, that is, when magne-
sium treatment in the OB animals induced increased P-S845
of the GluA1 subunit level in the PFC (168 % of NaCl sham,
p<0.01 vs. NaCl OB (a)) and when OB led to increased P-
S845 in the hippocampus (164 % of NaCl sham, p<0.05 vs.
NaCl sham). This effect was reversed by magnesium (66 % of
NaCl sham, p<0.01 vs. NaCl OB (b)). In the PFC, two-way
ANOVA indicated that there were no effect of OB [F(1, 24)=
4.01, p=0.0567], a significant effect of magnesium [F(1, 24)=
12.53, p=0.0017], and no significant interaction [F(1, 24)=
0.78, p=0.3869]. In the hippocampus, two-way ANOVA
indicated that there were no significant effect of OB [F(1,
Fig. 5 Changes in the protein levels of the GluA1 subunit of the AMPA
receptor induced by OB and magnesium treatment. The levels of the
GluA1 subunit were measured in the prefrontal cortex (a), the hippocam-
pus (b), and amygdala (c) of sham and OB rats, treated for 2 weeks with a
vehicle or magnesium. The values represent the mean ± SEM (n=7–8)
Fig. 6 Changes in the protein levels of the phospho-Ser-831-GluA1
subunit of the AMPA receptor induced by OB and magnesium treatment.
The levels of the phospho-Ser-831-GluA1 subunit were measured in the
prefrontal cortex (a), the hippocampus (b), and amygdala (c) of sham and
OB rats, treated for 2 weeks with a vehicle or magnesium. The values
represent the mean ± SEM (n=7–8). *p<0.05 vs. OB
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22)=2.78, p=0.1090], a very significant effect of magnesium
[F(1, 22)=12.77, p=0.0017], and a borderline interaction
[F(1, 22)=3.89, p=0.0613]. In the amygdala, two-way
ANOVA indicated that there were no significant effect of
OB [F(1, 26=0.29, p=0.5922], no significant effect of mag-
nesium [F(1, 26)=0.03, p=0.8721], and no significant inter-
action [F(1, 26)=0.07, p=0.7932].
Effects of OB and administration of magnesium on the BDNF
level
As shown in Fig. 8, the OB procedure and administration of
magnesium induced significant effects in the BDNF levels in
the OB rats in all examined structures: the PFC (by 129 % of
NaCl sham, p<0.05 vs. NaCl OB) (a), the hippocampus
(143 % of NaCl sham, p<0.05 vs. NaCl OB) (b), and the
amygdala (177 % of NaCl sham, p<0.05 vs. NaCl OB) (c). In
the PFC, two-way ANOVA indicated that there were no effect
of OB [F(1, 22)=0.01, p=0.9433], a significant effect of
magnesium [F(1, 22)=4.57, p=0.0438], and a significant
interaction [F(1, 22)=4.95, p=0.0367]. In the hippocampus,
two-way ANOVA indicated that there were no significant
effect of the OB [F(1, 24)=1.66, p=0.2093], no significant
effect of magnesium [F(1, 24)=1.37, p=0.2533], and a sig-
nificant interaction [F(1, 24)=7.13, p=0.0134]. In the amyg-
dala, two-way ANOVA indicated that there were no signifi-
cant effect of OB [F(1, 24)=1.19, p=0.2870], a very signifi-
cant effect of magnesium [F(1, 24)=9.33, p=0.0054], and no
significant interaction [F(1, 24)=0.3, p=0.5870].
Effects of OB and administration of magnesium
on the GluN2A and GluN2B mRNA level
As shown in Fig. 9, the OB procedure and administration of
magnesium in all cases did not affect the level of the mRNA
GluN2a subunit in the PFC. Two-way ANOVA indicated a
Fig. 7 Changes in the protein levels of the phospho-Ser-845-GluA1
subunit of the AMPA receptor induced by OB and magnesium treatment.
The levels of the phospho-Ser-845-GluA1 subunit were measured in the
prefrontal cortex (a), the hippocampus (b), and amygdala (c) of sham and
OB rats, treated for 2 weeks with a vehicle or magnesium. The values
represent themean ± SEM (n=7–8). **p<0.01 vs. OB, #p<0.01 vs. sham
Fig. 8 Changes in the protein levels of the BDNF induced by OB and
magnesium treatment. The levels of the BDNF were measured in the
prefrontal cortex (a), the hippocampus (b), and amygdala (c) of sham and
OB rats, treated for 2 weeks with a vehicle or magnesium. The values
represent the mean ± SEM (n=7–8). *p<0.05 vs. OB
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borderline effect of OB [F(1, 22)=3.12, p=0.9144], no sig-
nificant effect of magnesium [F(1, 22)=0.55, p=0.4654], and
no significant interaction [F(1, 22)=0.09, p=0.7665]. As
shown in Fig. 8b, the OB procedure significantly decreased
the level of GluN2AmRNA in the hippocampus (p<0.001 vs.
NaCl sham). Magnesium did not reverse these changes. Two-
way ANOVA indicated significant effects of OB [F(1, 26)=
7.05, p=0.0134] and magnesium [F(1, 26)=6.94, p=0.0140]
and a very significant interaction [F(1, 26)=12.69, p=
0.0014]. As shown in Fig. 9c, the OB procedure did not affect
the level of the GluN2B subunit mRNA level in the PFC, but
the administration of magnesium in sham and OB animals led
to a radical increase of the mRNA levels (p<0.0001 vs. sham
and p<0.0001 vs. NaCl OB, respectively). Two-way ANOVA
indicated that there were no significant effect of OB [F(1,
22)=2.29, p=0.1441], an extremely significant effect of mag-
nesium [F(1, 22)=142.84, p<0.0001], and a very significant
interaction [F(1, 22)=8.06, p=0.0095]. As shown in Fig. 9d,
the OB procedure significantly decreased (p<0.05 vs. NaCl
sham) the GluN2B subunit mRNA level in the hippocampus,
but the administration of magnesium in the sham and OB
animals caused an extreme increase in the mRNA levels
(p<0.0001 vs. NaCl sham, p<0.0001 vs. NaCl OB, respec-
tively). Two-way ANOVA indicated a significant effect of OB
[F(1, 26)=4.74, p=0.0387], an extremely significant effect of
magnesium [F(1, 26)=370.18, p<0.0001], and a borderline
interaction [F(1, 26)=3.53, p=0.0714].
Discussion
In the present study, our findings provided new insights
concerning the antidepressant-like activity of magnesium.
We demonstrated that all tested doses of magnesium (10, 15,
and 20 mg/kg) reduced hyperactivity in the open field test in
rats in the olfactory bulbectomy (OB) model of depression.
Because the increased hyperactivity in the open field test is
considered a consequence of stress and/or anxiety (Harkin
et al. 2003), these results appear to reinforce the general
hypothesis that supports both the antidepressant and anxiolyt-
ic activities of magnesium (Poleszak et al. 2004; Poleszak
et al. 2007).
In the present study, we also evaluated the magnesium
effects in the passive avoidance test in the OBmodel. A deficit
in the acquisition of the passive avoidance reflex is a well-
established memory and learning disruption that results from
OB (Kelly et al. 1997). In our study, the doses of 15 and
20 mg/kg of magnesium administered to OB rats were active
and significantly reduced the number of trials required for the
acquisition of a passive avoidance reflex compared with
untreated OB rats. The efficacy of magnesium in the
improvements of learning and memory observed in the
passive avoidance test supports previous findings by Slutsky
et al. (2010) who demonstrated the potential of magnesium to
enhance the processes of memory and learning in rats (Slutsky
et al. 2010). Lesion studies have conclusively demonstrated
Fig. 9 Changes in the mRNA levels of GluN2A and GluN2B subunits of
NMDA receptors induced byOB andmagnesium treatment. The levels of
the mRNA level were measured in the PFC and hippocampus of sham
and OB rats, treated for 2 weeks with a vehicle or magnesium. The values
represent the mean±SEM (n=7–8). #p<0.05 vs. sham, ###p<0.001 vs.
sham, ****p<0.0001 vs. OB
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that the hippocampus and the amygdala are brain structures
specifically involved in the acquisition of a passive avoidance
reflex in rats (Slotnick 1973; Lorenzini et al. 1996; Ambrogi
Lorenzini et al. 1997). Furthermore, the amygdala and the
medial prefrontal cortex are also responsible for the formation
of fear memory (LeDoux 2000).
Because OB impaired glutamate transmission in the amyg-
dala, hippocampus, and cortical regions (Song and Leonard
2005; Van Riezen and Leonard 1990), we expected that the
depressive-like symptoms induced by OB and/or the
antidepressant-like activity of magnesium would be associat-
ed with the modulation of glutamatergic pathways. Our sup-
positions were enhanced by the fact that glutamate is a crucial
neurotransmitter engaged in memory and learning processes,
which are impaired by OB (Song and Leonard 2005). To
verify this hypothesis, we studied the effects of OB and
magnesium on the NMDAR and AMPAR receptor subunits.
Unexpectedly, we did not identify differences in the levels of
NMDAR and AMPAR subunits between the OB and sham
animals in any studied brain structures. These findings may
indicate the lack of an association between the levels of
glutamate receptors and the depressive-like symptoms in-
duced by OB. However, we cannot exclude that such changes
may occur, although in a different region or level of the
investigated brain structures.
On the other hand, the dose of 15 mg/kg of magnesium
significantly elevated the GluN2B subunit and BDNF protein
levels in the OB animals in the amygdala. These alterations
may play an important role in the antidepressant-like activity
of magnesium in OB, particularly in the passive avoidance
task. There are no specific data that indicate the role of the
glutamate system in the amygdala in the passive avoidance
task, but many reports that concern conditioned fear empha-
size the importance of NMDA-dependent transmission in the
amygdala in fear learning (Miserendino et al. 1990; Goosens
et al. 2003); for example, the injection of an NMDA antago-
nist into the amygdala inhibited the acquisition of fear condi-
tioning (Miserendino et al. 1990). Furthermore, OB induces
decreased binding of [3H] MK-801 to NMDARs in the amyg-
dala (Ho et al. 2001). In addition, the studies of Slutsky et al.
(2010) demonstrated that chronic administration of magne-
sium was associated with an increase in the BDNF and
GluN2B subunit levels in the hippocampus, which indicates
alterations that correlate with enhanced neuroplasticity. There-
fore, we suggest that increased BDNF and GluN2B subunit
levels in the amygdala may indicate the restoration of synaptic
connections damaged by bulbectomy (Harkin et al. 2003;
Song and Leonard 2005) and the normalization of neural
transmission between the amygdala and other brain structures.
In contrast to the amygdala, the administration of magne-
sium did not lead to changes in the NMDAR subunit protein
levels in the hippocampus or the PFC in OB rats. These results
did not correlate with the mRNA levels. We determined that
magnesium led to increased GluN2B subunit mRNA in the
PFC and the hippocampus in the sham and OB rats. Further-
more, the mRNA levels of GluN2A and GluN2B subunits in
the hippocampus of the OB rats were decreased compared
with the sham animals. The lack of a similar pattern in the
protein and mRNA expressions may be explained, in part, by
the differences in the detection limits of the applied methods.
Moreover, other factors, such as the translational regulation
receptor half-life, can significantly contribute to the obtained
results. Based on our previous studies, we also suspected that
2 weeks of magnesium administration was too short of a
period to achieve elevated GluN2B subunits in the PFC.
Previously, we demonstrated that 5 weeks of magnesium
treatment in CMS animals led to an increased GluN2B protein
level in the PFC (Pochwat et al. 2014).
We previously discussed that magnesium elevated the ex-
pression of BDNF in the amygdala in the OB animals.We also
noticed similar events in the hippocampus and the PFC in the
OB animals. However, it is difficult to interpret the enhanced
expression of BDNF after magnesium treatment in the OB
group as the reverse of OB-induced changes because we did
not observe significant differences in the BDNF levels be-
tween the OB and sham animals. Our results are consistent
with other studies performed in rats, which demonstrated no
significant differences in the expression of BDNF at the
protein (Luo et al. 2010) or mRNA levels (Van Hoomissen
et al. 2003) after OB. Thus, the BDNF involvement in the
depressive-like symptoms evoked by OB appears to be more
complex.
Interestingly, we identified elevated levels of BDNF and
the P-S831 and P-S845 of the GluA1 subunit of AMPARs in
the PFC of the OB rats after magnesium treatment. The
phosphorylation of these residues of serine represents crucial
events for trafficking and inserting the GluA1 subunit of
AMPARs into the synapse. AMPAR activation, together with
BDNF release, is a fundamental condition for the processes of
neuroplasticity (Lee et al. 2010; Lee and Kirkwood 2011;
Duman and Voleti 2012). As has been shown in numerous
studies, the insertion of the GluA1 subunit of AMPARs into
the synapse, followed by the subsequent stimulation of the
AMPAR GluA1 containing subunit, is a crucial event for the
antidepressant mechanism of ketamine (Li et al. 2010), as well
as drugs with a slow onset of action, such as fluoxetine
(Svenningsson et al. 2002) or tianeptine (Svenningsson et al.
2007; Duman et al. 2012). These findings suggest that
AMPAR activation, enhanced AMPAR transmission, and en-
hanced BDNF levels in the PFCmay be potential mechanisms
of action for the antidepressant-like activity of magnesium in
OB rats. However, some issues require further studies.
It is well known that ketamine, which is also an NMDA
antagonist, exerts its antidepressant-like activity in CMS after
a single dose (Li et al. 2010). In our previous studies, we
demonstrated that 3 weeks of treatment with magnesium was
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required to achieve the antidepressant-like activity in the CMS
(Pochwat et al. 2014). On the other hand, it is well known that
blockade of the NMDA receptor is essential for the
antidepressant-like activity of a single dose of magnesium in
the FST (Poleszak et al. 2007). It is likely that the molecular
consequences of ketamine and magnesium administration, to
some extent, may be similar, although the time required for
their occurrence may be different. The administration of a
very small dose of ketamine (0.5 mg/kg) required 11 days of
treatment to achieve its antidepressant effect in the FST. This
effect was associated with the phosphorylation of mTOR and
an increased BDNF level in the hippocampus (Akinfiresoye
and Tizabi 2013). It appears that despite the similar binding
sites of ketamine and magnesium on NMDARs, different
affinities of magnesium and ketamine to the NMDARs and
differences in the pharmacokinetic profiles are the main fac-
tors that differentiate the onset of action and the profile of the
antidepressant-like activity of these compounds (Orser et al.
1997).
In contrast to the PFC, we did not identify associations
between increased BDNF levels and enhanced phosphoryla-
tion of AMPARs in the hippocampus. Additionally, we ob-
served an increased level of P-S845 of the GluA1 in OB rats,
which was attenuated by magnesium treatment. Several stud-
ies have revealed that P-S845 in the dentate gyrus of the
hippocampus may be responsible for amphetamine-induced
hyperactivity and the imipramine-dependent triggering of a
manic state in bipolar disorder (Du et al. 2008). Magnesium’s
ability to cause dephosphorylation of P-S845 of AMPARs
may be a possible explanation of its potential to decrease
hyperactivity in the open field test observed in OB rats. Using
the data previously described as our basis, we suggest that the
potential of magnesium to enhance the BDNF level in OB rats
and the differentiated effects on AMPARs in the hippocampus
and the PFC may be the primary mechanisms responsible for
the effectiveness of magnesium in depression animal models,
i.e., the OB model, as well as anxiety animal models.
To summarize, our present study demonstrated that magne-
sium reversed behavioral abnormalities, such as the deficit in the
passive avoidance test or hyperactivity in the open field test,
evoked by the removal of the olfactory bulbs. These effects were
not accompanied by changes in the expression of GluN2A,
GluN2B, or GluA1 subunits of glutamate ionotropic receptors
in the examined brain structures. Although OB is an invasive
procedure associatedwith neural damage, significant fluctuations
in the BDNF levels have not been observed. Thus, direct in-
volvement of these proteins in the induction of depressive-like
behaviors appears to be irrelevant or at least unclear. The admin-
istration of magnesium in OB rats induced significant AMPAR
alterations and increased BDNF levels in the PFC comparedwith
the OB animals treated with saline. The BDNF level was also
elevated in the hippocampus and the amygdala. However,
AMPAR activation was only observed in the PFC, which indi-
cates the functional relationship between these pathways. Com-
bined with our previous results concerning magnesium activity
in CMS, these findings suggest that magnesium is a potential
therapeutic solution in patients with mood disorders associated
with anhedonia, agitation, and anxiety.
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